Related Experiment Video
Updated: Jun 27, 2026
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke
Maria Philip1, Michael Benatar, Marc Fisher
1Department of Neurology, University of Texas Houston Medical School, Houston, TX 77030, USA.
Background And Purpose:
Numerous neuroprotective agents have proven effective in animal stroke studies, but every drug has failed to achieve its primary outcome when brought forward to clinical trials. We analyzed the quality and adequacy of animal studies supporting the efficacy of NXY-059 and other neuroprotective agents that are currently being investigated in phase II/III trials.
Methods:
We conducted a systematic search of all neuroprotective drugs in Phase II or III trials and collected data from animal studies of focal cerebral ischemia testing agents systemically administered within 24 hours of occlusion. The methodological rigor of each individual study was evaluated using 5 criteria derived from the STAIR guidelines. The adequacy of the preclinical "package" for each drug was then evaluated by combining the results of all studies for each drug to determine which of a further 5 STAIR criteria were met before moving forward from animal to human studies.
Results:
Our search yielded 13 agents of which 10 had published data in peer-reviewed journals. There is substantial within-drug variability in the quality of preclinical studies as well as substantial variation in the completeness of the collective preclinical literature for different drugs. There has been little or no improvement in the quality of animal studies since NXY-059, and current agents have not been subjected to a more complete preclinical evaluation.
Conclusions:
There is significant heterogeneity in the quality of animal testing for neuroprotective agents in stroke. Drugs in the post-SAINT era have not been subjected to more thorough preclinical evaluation.
Insights
Preclinical animal studies for neuroprotective stroke drugs show variable quality and incomplete evaluation. Despite numerous agents, clinical trial success remains elusive due to inadequate research rigor.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Many neuroprotective agents effective in animal stroke models fail in human clinical trials.
- The translation gap between preclinical efficacy and clinical outcomes for stroke treatments is a persistent challenge.
Purpose of the Study:
- To analyze the quality and adequacy of animal studies supporting neuroprotective agents in phase II/III clinical trials.
- To evaluate the preclinical research supporting NXY-059 and other investigational neuroprotective drugs.
Main Methods:
- Systematic search for neuroprotective drugs in Phase II/III trials.
- Evaluation of animal focal cerebral ischemia studies using STAIR guideline criteria.
- Assessment of preclinical data completeness for each drug before clinical advancement.
Main Results:
- 13 agents were identified; 10 had published preclinical data.
- Significant variability exists in study quality and literature completeness for different drugs.
- No improvement in animal study quality or preclinical evaluation thoroughness since NXY-059.
Conclusions:
- Substantial heterogeneity in the quality of preclinical animal testing for stroke neuroprotective agents.
- Current agents in clinical trials have not undergone more rigorous preclinical evaluation compared to earlier drugs.